Becker Business Podcast – Episode Summary

Episode: GoodRx: Is it Today’s Hims & Hers?
Host: Scott Becker
Date: August 18, 2025

Overview

This episode examines the significant business developments surrounding GoodRx and its parallels with the meteoric rise of Hims & Hers, particularly in the telehealth-driven weight loss drug market. Scott Becker delves into GoodRx's surging stock performance, recent deals, and how the overall GLP-1 weight loss drug sector is reshaping the pharmaceutical and telehealth industries. The episode also touches on Novo Nordisk's major price cut for Ozempic and wider trends impacting the market.

Key Discussion Points and Insights

1. GoodRx's Major Uptick Following a New Deal

• GoodRx stock up 30% after announcing a deal to sell popular weight loss drugs Ozempic and Wegovy.
  • “Goodrx is on a tier today. It's up 30% after cutting a deal to sell Ozempic and Wegovy.” (00:12)
• Becker emphasizes how this development places GoodRx in a similar business position to Hims & Hers, known for its telehealth pharmaceutical sales.

2. Hims & Hers' Explosive Growth via Weight Loss Drugs

• Hims & Hers initially gained notoriety for erectile dysfunction drugs but “really compounded and grew incredibly based on the ability to sell these weight loss drugs through telehealth and more.” (00:33)
• Their stock performance:
  • “It's been up an absolute tremendous amount year to date and over the last 52 weeks.” (00:43)
  • Concrete data: “Hims and hers is up 86% year to date.” (01:04)

3. Novo Nordisk’s Price Cut for Ozempic

• Novo Nordisk, after significant stock decline (“down more than 60%”), announces a plan to cut the price of Ozempic by 50% for cash buyers.
  • “Novo Nordisk... announced today that they're going to cut the price for people that are buying directly their drug Ozempic, that they're going to cut the price for cash buyers in half.” (00:53)
  • New price point: “That's going to be about 500 a month versus 1,000 a month.” (00:58)
  • Later reconfirmed: “Novo Nordisk is going to offer Ozempic at first 4.99 a month to US customers.” (02:08)
• Commentary on commoditization: “These prices will keep on going down as they become more commoditized.” (01:00)

4. Weight Loss Market Insights and Investment Reflections

• Comparison of GoodRx and Hims & Hers as potential investment opportunities.
  • “The question becomes, does Goodrx, is it able to go on a tier as it opens itself up to these weight loss drugs and selling those? Really, really interesting story this morning.” (01:07)
  • Humble hindsight: “Yes. I wish I owned it. It's only up 5% year to date. HIMS and hers is up 85% year to date...” (01:16)
• Personal tone regarding weight control, relatable to much of the audience:
  • “For all of those. All of us that struggle a little bit with weight loss and weight control. God bless us.” (01:22)

Notable Quotes & Memorable Moments

• On GoodRx's Surge:
  • “GoodRx is on a tier today. It's up 30% after cutting a deal to sell Ozempic and Wegovy.” (00:12)
• On Hims & Hers Transformation:
  • “It then really compounded and grew incredibly based on the ability to sell these weight loss drugs through telehealth and more. So just exploded.” (00:34)
• On Market Trends:
  • “These prices will keep on going down as they become more commoditized.” (01:00)
• Investment Hindsight:
  • “Yes. I wish I owned it. It's only up 5% year to date. HIMS and hers is up 85% year to date...” (01:16)
• Human Moment:
  • “For all of those. All of us that struggle a little bit with weight loss and weight control. God bless us.” (01:22)

Key Timestamps

• 00:12 – GoodRx’s 30% surge and new weight loss drug deal
• 00:34 – Hims & Hers’ shift and explosive growth
• 00:53 – Novo Nordisk’s 50% Ozempic price cut for cash buyers
• 01:04 – Year-to-date performance for Hims & Hers
• 01:16 – Investment reflections on GoodRx and Hims & Hers
• 01:22 – Personal commentary on weight control and the drug market
• 02:08 – Reconfirmation of Ozempic’s new price ($499/month)

Wrap-Up

Scott Becker provides an engaging update on the dynamic weight loss drug and telehealth landscape, highlighting how GoodRx could replicate Hims & Hers’ success by entering the GLP-1 (Ozempic, Wegovy) space. With major pricing changes from Novo Nordisk and the commoditization of these popular drugs, this episode offers quick but insightful analysis for investors and those curious about the future of telehealth-driven pharmaceuticals.